109166 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal Peptide nucleic acid, PNA
G-rich polynucleotides for the treatment of Huntington's Disease
#302Modulation of eIF4E expression
#303Method for selective inhibition of human N-myc gene in N-myc expressing tumors through antisense and antigen peptido-nucleic acids (PNA)
#304Oligomeric compounds and compositions for use in modulation of pri-mirnas
#305Methods of using molecular constructs for detection of biochemical reactions
#306Antigene oligomers inhibit transcription
#307Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
#308Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#309Genetic suppression and replacement
#310Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus
#311Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#312Oligonucleotides labeled with stable isotopes and a method for detecting the same
#313Methods, compositions, and kits comprising PNA for RNA interference
#314Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, FBH58295FL, 57255, and 57255alt molecules and uses therefor
#315Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#316PNA conjugate for treating chronic myeloid leukemia (CML)
#317Human RNase III and compositions and uses thereof
#318Antisense oligonucleotides against tenascin for the treating of vitiligo
#319Antisense oligonucleotide preparation method
#320Antisense inhibition via RNAse H-independent reduction in mRNA
#321Novel peptide-conjugated oligomeric compounds
#322Compounds and methods for diagnostic imaging and therapy
#323Chimeric molecules to modulate gene expression
#324Higher order structure and binding of peptide nucleic acids
#325Methods for the treatment of neoplastic disorders with anti-caveolin agents
#326Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
#327Non-phosphorous-linked oligomeric compounds and their use in gene modulation